Latest Market Access News

BluGlass has begun a three-to-five-month, A$286,000 feasibility collaboration with global photonics company Coherent to develop a novel gallium nitride device for scientific and medical applications. The agreement offers technical and commercial promise, but does not yet include a production commitment or confirmed product launch.

Memphasys has signed a three-year exclusive distribution agreement covering the Czech Republic, Slovakia and Kazakhstan, with minimum purchases worth approximately A$674,000. The deal expands Felix’s European footprint while adding dedicated commercial leadership in the region.

EMVision has completed the first stage of a Melbourne Mobile Stroke Unit study, operating its portable brain scanner in homes, ambulances and a workplace. The small, non-diagnostic feasibility study produced strong usability results while pointing to a larger clinical validation step planned for next-generation units.

Environmental Clean Technologies says its proposed Xenica acquisition has gained a defence-market sublicence for MXenes, adding a potential route to customers for its Flash Joule Heating platform. The agreement is not a customer contract, and revenue still depends on acquisition completion, repeatable production and qualification.

PT ANTAM (Persero) Tbk (ASX:ATM) reported Rp6.91 trillion in net profit and Rp62.71 trillion in first-half 2026 sales, with gold contributing the bulk of disclosed revenue. The Indonesian miner is also advancing downstream projects across gold, nickel and bauxite, although project costs and completion dates remain undisclosed.

Emyria has secured a limited in-person speaking position at a US FDA hearing examining how psychedelic medicines could be delivered safely and at scale. The appearance gives the ASX-listed company a regulatory platform, but does not represent FDA approval, funding or a commercial agreement.

Osmond Resources reported a A$7.61 million FY26 loss and warned of a material uncertainty over its ability to continue as a going concern, despite holding A$5.50 million in cash. The company is betting its Spanish Orión project can move from exploration into a resource estimate and scoping study in the coming months.

Energy One Limited (ASX:EOL) reported a robust FY2026 with a 17% increase in recurring revenue and a 51% jump in net profit before tax, while preparing for a transformative acquisition of Gas Management Services Limited to deepen its European market presence.

Australian Bond Exchange Holdings (ASX: ABE) reported a 47% revenue increase to $3.55 million for FY26, cutting its loss after tax by nearly two-thirds to $1.51 million amid ongoing going concern uncertainty.

Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.

Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.

BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.